The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...

Biogen has decided to close down its digital ... competition and spinal muscular atrophy (SMA) treatment Spinraza (nusinersen), which has seen its growth stalled by rival therapies entering ...

Motor improvements in SMA adults treated with Spinraza paralleled a boost in electrical impulses along nerves that supply ...

The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi (lecanemab) for early Alzheimer’s disease (AD). The regulatory body has ...

Biogen Inc. (NASDAQ:BIIB – Free Report) – Analysts at Leerink Partnrs decreased their Q2 2025 earnings per share (EPS) estimates for Biogen in a research report issued on Sunday, April 13th.

Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease. This authorisation makes the amyloid-beta (Aβ ...

Also Read: Alzheimer’s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding Protofibrils are a key toxic form of Aβ that accumulate in the brain and cause neuronal injury.

Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi behind them and focus on the drug's launch in the region. After months of ...